These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines. Konadu E, Robbins JB, Shiloach J, Bryla DA, Szu SC. Infect Immun; 1994 Nov; 62(11):5048-54. PubMed ID: 7927787 [Abstract] [Full Text] [Related]
23. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Fattom AI, Sarwar J, Ortiz A, Naso R. Infect Immun; 1996 May; 64(5):1659-65. PubMed ID: 8613375 [Abstract] [Full Text] [Related]
24. Immunogenicity of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered to victims of acute trauma. Campbell WN, Hendrix E, Cryz S, Cross AS. Clin Infect Dis; 1996 Jul; 23(1):179-81. PubMed ID: 8816151 [Abstract] [Full Text] [Related]
25. Use of Pseudomonas aeruginosa toxin A in the construction of conjugate vaccines and immunotoxins. Cryz SJ, Fürer E, Sadoff JC, Germanier R, Pastan I, Willingham MC, FitzGerald DJ. Rev Infect Dis; 1987 Jul; 9 Suppl 5():S644-9. PubMed ID: 3120274 [Abstract] [Full Text] [Related]
26. Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine. Weinberg GA, Einhorn MS, Lenoir AA, Granoff PD, Granoff DM. J Pediatr; 1987 Jul; 111(1):22-7. PubMed ID: 3110388 [Abstract] [Full Text] [Related]
27. Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers. Cross A, Artenstein A, Que J, Fredeking T, Furer E, Sadoff JC, Cryz SJ. J Infect Dis; 1994 Oct; 170(4):834-40. PubMed ID: 7523536 [Abstract] [Full Text] [Related]
28. Phase I clinical trial of O-acetylated pectin conjugate, a plant polysaccharide based typhoid vaccine. Szu SC, Lin KF, Hunt S, Chu C, Thinh ND. Vaccine; 2014 May 07; 32(22):2618-22. PubMed ID: 24657719 [Abstract] [Full Text] [Related]
30. Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease. Molrine DC, George S, Tarbell N, Mauch P, Diller L, Neuberg D, Shamberger RC, Anderson EL, Phillips NR, Kinsella K, Ambrosino DM. Ann Intern Med; 1995 Dec 01; 123(11):828-34. PubMed ID: 7486464 [Abstract] [Full Text] [Related]
31. Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children. Ahmed A, Li J, Shiloach Y, Robbins JB, Szu SC. J Infect Dis; 2006 Feb 15; 193(4):515-21. PubMed ID: 16425130 [Abstract] [Full Text] [Related]
32. Response of 7- to 15-month-old infants to sequential immunization with Haemophilus influenzae type b-CRM197 conjugate and polysaccharide vaccines. Rothstein EP, Schiller RP, Girone JA, Hipp TJ, Souder RL, Bernstein HH, Madore DV, Johnson CL, Smith DH. Am J Dis Child; 1991 Aug 15; 145(8):898-900. PubMed ID: 1858727 [Abstract] [Full Text] [Related]
34. Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A. Fries LF, Gordon DM, Schneider I, Beier JC, Long GW, Gross M, Que JU, Cryz SJ, Sadoff JC. Infect Immun; 1992 May 15; 60(5):1834-9. PubMed ID: 1563771 [Abstract] [Full Text] [Related]
35. Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys. Devi SJ, Zollinger WD, Snoy PJ, Tai JY, Costantini P, Norelli F, Rappuoli R, Frasch CE. Infect Immun; 1997 Mar 15; 65(3):1045-52. PubMed ID: 9038314 [Abstract] [Full Text] [Related]
36. Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. Cohen D, Ashkenazi S, Green M, Lerman Y, Slepon R, Robin G, Orr N, Taylor DN, Sadoff JC, Chu C, Shiloach J, Schneerson R, Robbins JB. Infect Immun; 1996 Oct 15; 64(10):4074-7. PubMed ID: 8926071 [Abstract] [Full Text] [Related]
37. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Anderson EL, Bowers T, Mink CM, Kennedy DJ, Belshe RB, Harakeh H, Pais L, Holder P, Carlone GM. Infect Immun; 1994 Aug 15; 62(8):3391-5. PubMed ID: 8039909 [Abstract] [Full Text] [Related]
38. Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates. Qian F, Wu Y, Muratova O, Zhou H, Dobrescu G, Duggan P, Lynn L, Song G, Zhang Y, Reiter K, MacDonald N, Narum DL, Long CA, Miller LH, Saul A, Mullen GE. Vaccine; 2007 May 16; 25(20):3923-33. PubMed ID: 17428587 [Abstract] [Full Text] [Related]
39. Is Pseudomonas aeruginosa exotoxin A a good carrier protein for conjugate vaccines? Pier GB. Hum Vaccin; 2007 May 16; 3(2):39-40; author reply 41. PubMed ID: 17268204 [No Abstract] [Full Text] [Related]
40. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Richmond P, Goldblatt D, Fusco PC, Fusco JD, Heron I, Clark S, Borrow R, Michon F. Vaccine; 1999 Nov 12; 18(7-8):641-6. PubMed ID: 10547423 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]